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Hepatocellular carcinoma (HCC) often arises from chronically diseased livers. Persistent
liver inﬂammation causes the accumulation of excessive extracellular matrix (ECM) pro-
teins and impairs the liver function, ﬁnally leading to the development of HCC. A pleiotropic
cytokine, transforming growth factor (TGF)-β1, plays critical roles throughout the process
of ﬁbrogenesis and hepatocarcinogenesis. In the liver, TGF-β1 inhibits the proliferation of
hepatocytes and stimulates the production of ECM from hepatic stellate cells (HSCs) to
maintain tissue homeostasis. During disease progression, both growth factors/cytokines
and the ECM alter the TGF-β1 signals by modifying the phosphorylation of Smad proteins
at their C-terminal and linker regions. TGF-β1 stimulates the expression of integrins, cel-
lular receptors for ECM, along with an increase in ECM accumulation. The activation of
integrins by the ECM modulates the response to TGF-β1 in hepatic cells, resulting in their
resistance to TGF-β1-induced growth suppression in hepatocytes and the sustained pro-
duction of ECM proteins in activated HSCs/myoﬁbroblasts. Both growth factor receptors
and integrins modify the expression and/or functions of the downstream effectors of TGF-
β1, resulting in the escape of hepatocytes fromTGF-β1-induced apoptosis. Recent studies
have revealed that the alterations of Smad phosphorylation that occur as the results of
the crosstalk between TGF-β1, growth factors and integrins could change the nature of
TGF-β1 signals from tumor suppression to promotion.Therefore, the modiﬁcation of Smad
phosphorylation could be an attractive target for the prevention and/or treatment of HCC.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common
malignant neoplasms in the world and it is closely associated with
many risk factors, including hepatitis B and C virus infection,
alcoholic liver disease, non-alcoholic fatty liver diseases related to
obesity and/or diabetes, aﬂatoxin B1 contamination of food, and
less frequently, genetic predisposition. The incidence of HCC is
increasing worldwide, mainly due to the spread of chronic infec-
tions with hepatitis B and C viruses (Okuda, 2000; LIovet et al.,
2003; El-Serag andRudolph,2007).Most of these risk factors cause
persistent inﬂammation in the liver, leading to the formation of
liver cirrhosis characterized by an excessive accumulation of the
Abbreviations: CDK, cyclin-dependent kinase; ECM, extracellular matrix; EGF,
epidermal growth factor; EMT, epithelial to mesenchymal transition; ERK, extra-
cellular signal-regulated kinase; FAK, focal adhesion kinase; HBV, hepatitis C virus;
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HSC, hepatic stellate cells;
IFN, interferon; IGF, insulin-like growth factor; IL, interleukin; ILK, integrin-linked
kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase;
MFB, myoﬁbroblast; PDCD4, programmed cell death 4; PDGF, platelet-derived
growth factor; PI3K, phosphoinositide-3 kinase; PKC, protein kinase C; pSmadC,
C-terminally phosphorylated Smad; pSmadL, linker-phosphorylated Smad; TGF-
β1; transforming growth factor-β; TNF-α, tumor necrosis factor-α; VEGF, vascular
endothelial growth factor.
collagen-rich extracellular matrix (ECM). The progression of liver
ﬁbrosis to cirrhosis is closely associated with the development of
HCC based on both clinical observations and evidence in experi-
mental animal models (Tsukuma et al., 1993; Sakaida et al., 1998;
Yoshida et al., 1999; El-Serag and Rudolph, 2007; Giannelli et al.,
2011).
Transforming growth factor (TGF)-β1 plays critical roles in
hepatic ﬁbrogenesis, hepatocarcinogenesis, and HCC progression
(Inagaki and Okazaki, 2007; Friedman, 2008; Giannelli et al.,
2011). TGF-β is a member of a large family of multifunctional
cytokines, and consists of three isoforms calledTGF-β1,β2, andβ3,
which share 80% homology in their amino acid sequences. TGF-
β1 binds to its speciﬁc TGF-β receptor complex, consisting of the
TGF-β type I receptor (TβRI) and type II receptor (TβRII), then
TβRI phosphorylates the Smad2 and Smad3 transcription factors
(TFs; Moses et al., 1990; Heldin et al., 1997; Massague et al., 2005).
Phosphorylated Smad2 and Smad3 subsequently bind to Smad4
and translocate to the nucleus to initiate target gene expression.
Several groups have reported the presence of a Smad-independent
TGF-β1 activation pathway (Bhowmick et al., 2001; Derynck and
Zhang, 2003;Moustakas andHeldin, 2005;Yi et al., 2005;Giannelli
et al., 2011). TGF-β1 has been shown to rapidly activate ras and
several members of the mitogen-activated protein kinase (MAPK)
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pathways, such as extracellular signal-regulated kinase (ERK), p38,
and c-Jun N-terminal kinase (JNK) in several cell types. TGF-
β1 can also stimulate the phosphoinositide-3 kinase (PI3K)-Akt
pathway and Rho-like GTPases (Figure 1).
In the liver TGF-β1 is a potent growth inhibitor of normal
hepatocytes and HCC cells, and induces apoptosis and cellular
senescence in these cells (Lin and Chou, 1992; Oberhammer et al.,
1992; Siegel and Massague, 2003; Senturk et al., 2010). However,
TGF-β1 is highly expressed in many malignant tumors, including
HCC, and tumor cells are frequently thought to have lost their sen-
sitivity to TGF-β1 (Ito et al., 1991; Bedossa et al., 1995; Tsai et al.,
1997; Caja et al., 2007). During the disease progression, numerous
growth factors/inﬂammatory cytokines such as TGF-β1, hepato-
cyte growth factor (HGF), platelet-derived growth factor (PDGF),
vascular endothelial growth factor (VEGF), tumor necrosis factor-
α (TNF-α), interleukins (ILs), and interferons (IFNs) are released
from various types of hepatic cells and participate in apopto-
sis, inﬂammation, cell proliferation, tissue ﬁbrosis/remodeling,
and HCC development/progression (Inagaki and Okazaki, 2007;
Friedman, 2008). While TGF-β1 inhibits hepatocyte proliferation
in the early stage of liver injury, it stimulates the proliferation
of ﬁbroblasts and induces the expression of ECM genes, includ-
ing ﬁbrillar collagens, to repair the injured tissue. When injurious
stimulation is repeated, as occurs during persistent hepatitis virus
infection, the production of ECM continues, and ﬁbrous materials
accumulate, thus leading to the formation of cirrhosis that predis-
poses the liver to HCC (El-Serag and Rudolph, 2007; Giannelli
et al., 2011; Figure 2). Along with the progression of ﬁbrogene-
sis, an increased expression of integrin, a cell surface receptor for
FIGURE 1 |TheTGF-β signaling pathway.Three distinct forms of TGF-β,
TGF-β1, -β2, and -β3, can bind to the heterodimeric TGF-β receptor complex,
consisting of the type I receptor (TβRI) and type II receptor (TβRII). Once
TGF-β1 binds to the receptor complex, intracellular Smad2 and Smad3 are
recruited and phosphorylated byTβRI at their C-terminal SSXS motif.
Phosphorylated Smad2 and Smad3 subsequently bind to Smad4 and
translocate to the nucleus to initiate target gene expression in collaboration
with co-factors and other transcription factors (TFs). TGF-β can also activate
the PI3K, RhoA, TAK1, and Ras/MAPK pathways in a Smad-independent
manner.
the ECM, is observed (Volpes et al., 1991; Couvelard et al., 1993;
Levine et al., 2000). Integrins interact with growth factor receptors,
including TGF-β1 as well as with ECM proteins, and can modulate
the signal transduction pathways (Hayashida, 2010; Margadant
and Sonnenberg, 2010). Recent data indicate that during the pro-
gression of chronic hepatitis, from cirrhosis to HCC, changes in
theTGF-β1-induced Smadphosphorylationpattern occur, and the
alternatively phosphorylated Smad proteins (pSmadL) exert dis-
tinct transcriptional activities (Matsuzaki et al., 2007; Matsuzaki,
2011).
In this manuscript we review the effects of growth factor-
mediated signals and integrin-mediated signals on the tumor
suppressive signals induced by TGF-β1 in liver epithelial cells
and discuss the mechanisms regulating the phosphorylation of
the Smad protein as potential therapeutic targets.
LIVER FIBROSIS, HCC, AND INTEGRINS
Among the various growth factors and proinﬂammatory cytokines
involved in the long-lasting process of liver ﬁbrogenesis and hepa-
tocarcinogenesis, TGF-β1 plays critical roles throughout the pro-
gression of the disease (Inagaki and Okazaki, 2007; Friedman,
2008; Giannelli et al., 2011; Matsuzaki, 2011). Once the liver
injury is initiated and continued, hepatic stellate cells (HSCs),
the main source of ECM production in the liver, are activated
by TGF-β1 and proinﬂammatory cytokines. Sustained expression
of ECM genes by TGF-β1 in the activated HSCs and myoﬁ-
broblasts leads to the accumulation of collagenous ECM proteins
(Furukawa et al., 2003; Inagaki and Okazaki, 2007; Matsuzaki,
2011).
TGF-β1 is known to increase the expression of integrins, major
cellular receptors for ECM proteins, as well as its ligands, the ECM
proteins (Hayashida, 2010; Margadant and Sonnenberg, 2010).
With the progression of liver ﬁbrosis, the expression of integrins
is also increased (Couvelard et al., 1993; Volpes et al., 1993; Levine
et al., 2000). The integrins are large family of heterodimeric cell
surface receptors consisting of 18 α- and 8 β-transmembrane
subunits. Integrins can directly bind to ECM components and
transmit the signals from theECMto the cell interior and vice versa
(Hynes, 2002). The short cytoplasmic tails of integrins are asso-
ciated with adaptor proteins including Src, focal adhesion kinase
(FAK), integrin-linked kinase (ILK), kindlin1, paxilin, talin, vin-
culin, and PINCH. These integrin-associated proteins not only
transmit signals from the extracellular environment, but also
increase integrins activation. Integrin also interactswith cytoskele-
tal proteins and can regulate the cellular shape and motility upon
activation (Figure 3). Among the various integrin-associated pro-
teins, kinases such as Src, FAK, or ILK activate the cellular signal
transduction pathways including MAP kinase pathways (ERK,
p38, JNK), PI3K/Akt pathways, and protein kinase C (PKC) cas-
cades (Hynes, 2002; Hehlgans et al., 2007; Bottcher et al., 2009;
Millard et al., 2011). Integrins have also been shown to inter-
act with growth factor receptors including IGF-IR, PDGFR-β,
c-Met, and EGFR (Alam et al., 2007; Desgrosellier and Cheresh,
2010; Ivaska and Heino, 2010). Similarly, integrins can modulate
the TGF-β1/Samad pathways directly or indirectly via different
mechanisms, while TGF-β1 stimulates the expression of integrins
(Margadant and Sonnenberg, 2010).
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FIGURE 2 |Transforming growth factor-β1, fibrosis, and HCC.When
hepatocytes are injured by agents such as hepatitis viruses, various growth
factors, and proinﬂammatory cytokines, as well as TGF-1β1 are released from
non-parenchymal liver cells. In the earlier stages, growth factors stimulate the
proliferation of hepatocytes to restore the liver function, while TGF-β1 induces
the apoptosis of injured hepatocytes to maintain tissue homeostasis. If the
injurious stimuli are persistent, ECM protein production from the activated
HSCs/myoﬁbroblasts is continuously stimulated. Both persistent
inﬂammation and the accumulated ECM proteins contribute to the alteration
of signal transduction pathways in regenerated hepatocytes, along with the
accumulation of genetic mutations, which leads to the preneoplastic changes
of hepatocytes and the eventual development of HCC.
FIGURE 3 | Integrins, adaptor proteins, and signaling pathways.When
ECMs bind to integrin receptors and form focal adhesions, the cytoplasmic
tails of β-integrins are associated with a number of adaptor proteins. Talin
forms a contact with both the β-integrin tail and the actin cytoskeleton. ILK
associates with actin through its partners such as parvin, PINCH and
kindling. FAK is responsible for the binding of integrin-associated proteins
like paxillin and talin. These integrin-associated proteins involve
non-receptor type kinases, such as Src, FAK, or ILK, which activate cellular
transduction pathways, including the MAP kinase pathways, PI3K/Akt
pathways and PKCs. Integrins are also associated with cytoskeletal proteins
through the adaptor proteins, and can regulate cellular shape and motility.
Based on this information, it has been speculated that an
increased expression of integrins on the hepatocytes in a ﬁbrotic
liver could also modulate the intracellular signaling pathways and
contribute to the development of HCC. The expression of several
integrin subunits, including the α1, α2, α3, α5, α6, and β1 chains,
is also upregulated in HCC cells, and their expression patterns are
distinct from those of non-cancerous liver tissue (Volpes et al.,
1993; Begum et al., 1995; Ozaki et al., 1998; Lai et al., 2011). Fur-
thermore integrin α6 chain expression is correlated with a poor
prognosis for HCC patients (Ke et al., 2011). Integrinsα1β1, α2β1
α3β1, andα6β1 play key roles in the invasion of HCC cells (Carloni
et al., 2001; Giannelli et al., 2001; Torimura et al., 2001; Yang et al.,
2006) and integrinsα3β1 and α6β4 promote the growth of HCC
cells upon activation by their ligand, laminin-5 (Bergamini et al.,
2007). These data strongly suggest the important roles of the cell-
ECM interactions through integrin receptors in the progression of
HCC.
MECHANISMS OF RESISTANCE TO TGF-β1-INDUCED
APOPTOSIS IN LIVER EPITHELIAL CELLS
Transforming growth factor-β1 has a dual role in the development
and progression of HCC. TGF-β1 is a potent growth inhibitor of
normal hepatocytes and HCC cells and induces apoptosis in these
cells, and as a result, it is regarded as a tumor-suppressive cytokine.
However, TGF-β1 is able to promote the growth, invasion, and
metastasis of HCC cells through the epithelial-mesenchymal tran-
sition (EMT; Bierie and Moses, 2006; Massague, 2008; Matsuzaki,
2011). The ability of TGF-β1 to inhibit or stimulate cancer pro-
gression is partly dependent on the tumor microenvironment,
including the presence of growth factors/inﬂammatory cytokines
and/or ECM proteins. During the progression of liver ﬁbrogene-
sis with chronic inﬂammation, the hepatocyte responsiveness to
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TGF-β1 changes, and cells become resistant to TGF-β1-induced
apoptosis, thus suggesting the existence of preneoplastic changes
of hepatocytes in cirrhotic livers (Ito et al., 1991).
GROWTH FACTORS AND TGF-β1-INDUCED APOPTOSIS
The presence of growth factors such as HGF and EGF that stimu-
late hepatocyte proliferation has been shown to affect the TGF-
β1-induced growth-suppressive signal in hepatocytes (Fabregat
et al., 1996; Murillo et al., 2005). Similar effects of growth factors
on TGF-β1 signals were observed in TGF-β1-sensitive HCC cells
(Mori et al., 2004; Caja et al., 2007). When TGF-β1 induces apop-
tosis in hepatic cells, several downstream molecules are involved
in the induction of apoptosis. For example, the activation of p38
by GADD45β (Yoo et al., 2003) and JNK activation by the Daxx
protein (Perlman et al., 2001) were reported to be involved in
TGF-β1-induced apoptosis in hepatocytes. In the human HCC
cell line, Hep3B, DAP kinase was reported to be induced by TGF-
β1 in a Smad-dependent manner, and to promote the apoptosis by
releasing cytochrome c from the mitochondria (Jang et al., 2002).
We recently reported that programmed cell death 4 (PDCD4) is
induced by TGF-β1 in a Smad-dependent manner, and promotes
apoptosis in Huh7 human HCC cells (Zhang et al., 2006). The
addition of EGF or the tumor promoter TPA inhibits TGF-β1-
induced apoptosis by suppressing the induction of PDCD4 by
TGF-β1. When TGF-β1 induces apoptosis, the activities of ERK,
PI3K/Akt/S6K are attenuated (Petritsch et al., 2000). Activation of
these pathways byEGForTPA,bothof which involve the activation
of PKCs, abolished TGF-β1-induced apoptosis in Huh7 cells, sug-
gesting the involvement of PKCs, as well as the ERK and PI3K/Akt
pathways, in the resistance to TGF-β1-induced growth inhibition
in HCC cells (Nakashima et al., 2010).
THE INTERACTION BETWEEN GROWTH FACTOR RECEPTORS AND
INTEGRINS
Interestingly, integrins have been reported to interact with sev-
eral growth factor receptors, including IGF-IR, PDGFR-β, c-Met,
VEGFR, and EGFR, as well as TGF-β receptors, and to mod-
ulate their downstream signals by different mechanisms (Alam
et al., 2007; Desgrosellier and Cheresh, 2010; Ivaska and Heino,
2010). PDGFR-β, a receptor tyrosine kinase receptor involved in
the activation of proﬁbrogenic HCS cells, is regulated by integrins.
Detachment of cells from the ECM decreases PDGFR autophos-
phorylation and protein expression, and re-plating of cells on
ﬁbronectin prevents the proteasomal degradation of the PDGFR
(Baron and Schwartz, 2000). The EGFR, a tyrosine kinase trans-
membrane glycoprotein that is regulated by cell adhesion through
β1-integrin (Reginato et al., 2003), interacts with many integrins.
Integrin β1 and the EGFR, as well as αvβ3 and the EGFR, co-
precipitate with Src kinase and p130Cas (Moro et al., 2002;Cabodi
et al., 2004).
Integrins also modulates the activity of c-MET, a receptor for
HGF, by regulating its ligand-independent tyrosine phosphoryla-
tion (Wang et al., 2001). Although HGF is a potent stimulator of
hepatocyte proliferation, it is known to inhibit the proliferation of
certain HCC cell lines, such as HepG2 (Tajima et al., 1991; Shiota
et al., 1992). When β1-integrin is overexpressed in HepG2 cells,
HGF promotes the growth of the cells overexpressing β1-integrin,
while the growth of wild-type and mock-transfected cells are
suppressed by HGF (Zhang et al., 2003). β1-integrin suppressed
the induction of p27 by HGF, a CDK inhibitor that inhibits cell
cycle progression, and also promoted the proteasomal degrada-
tion of p27 by increasing the expression of its E3-ubiquitin ligase,
Skp2. These ﬁndings indicate that β1-integrin-mediated signals
from the ECM and growth factor receptor-mediated signals are
cooperatively controlled and regulate the cellular functions and
behavior.
INTEGRINS AND TGF-β1-INDUCED APOPTOSIS
The ECM has been used as a substrate for hepatocyte culture,
and the presence of cell-matrix interactions in vitro was found
to contribute to the survival and the maintenance of the differ-
entiated functions of primary hepatocytes (Gómez-Lechón et al.,
1998; Hansen and Albrecht, 1999; Cukierman et al., 2001; Godoy
et al., 2009). Godoy et al. (2009) reported that the presence of
ECM collagen inhibited the apoptosis of primary cultured hepa-
tocytes induced by TGF-β1 in a Src/FAK-mediated Akt and p38-
dependent manner. During the progression of liver ﬁbrosis, TGF-
β1 stimulates the expression of both ECMs and integrins (Inagaki
and Okazaki, 2007; Hayashida, 2010). The activation of integrins
by the ECM in the liver reciprocally alters the response of cells to
TGF-β1, inducing resistance to TGF-β1-induced growth suppres-
sion in hepatocytes, and the sustained production of ECMproteins
in activated HSCs and myoﬁbroblasts. This interaction might fur-
ther enhance the survival of hepatocytes and ECM production
from HSCs by establishing a feed-forward loop between apoptosis
resistance and ﬁbrosis, and may therefore contribute to the pro-
gression from liver ﬁbrosis to cirrhosis, and the development of
preneoplastic changes in hepatocytes (Figure 4).
The resistance to apoptosis induced by ECM/integrins is also
observed in cancer cells. The presence of the ECM and activation
of integrin-mediated signals has been shown to inhibit cytotoxic
agent-induced apoptosis in a MAP kinase-dependent manner
(Sethi et al., 1999; Zhang et al., 2002). We have previously shown
that human HCC cells overexpressing β1-integrin become resis-
tant to TGF-β1-induced apoptosis compared to mock-transfected
cells in a MAP kinase-dependent manner (Zhang et al., 2004).
TGF-β1 is known to transiently activate the MAP kinase path-
way in a Smad-independent manner (Derynck and Zhang, 2003;
Moustakas and Heldin, 2005; Giannelli et al., 2011). An overex-
pression of β1-integrin in HCC cells was shown to induce the
activation of the MAP kinase pathway, and TGF-β1-induced the
further sustained activation of ERK, p38, and JNK. The inhibition
of these pathways reversed the TGF-β1-induced apoptosis, sug-
gesting that theMAP kinase pathway has critical roles in the escape
of cells from TGF-β1-induced apoptosis (Zhang et al., 2004).
Furthermore, recent reports have suggested that the physical
properties of the ECM, including the matrix stiffness, modu-
late the intracellular signaling and cellular behavior (Wells, 2008;
Tilghman et al., 2010; Zhao et al., 2010; Schrader et al., 2011).
Clinical observations indicated that the liver stiffness, as measured
by transient elastography,was closely associated with the degree of
liver ﬁbrosis and cirrhosis, and could predict the development of
HCC in patients with viral hepatitis (Masuzaki et al., 2009; Jung
et al., 2011). Primary cultured hepatocytes with a stiff collagen
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FIGURE 4 |The interactions betweenTGF-β1 and
ECM/integrin-mediated signaling in hepatocytes in the fibrotic liver.
Initially, TGF-β1 inhibits the growth of hepatocytes by inducing the
expression of pro-apoptotic molecules, such as PDCD4, via the formation of
pSmadC. TGF-β1 stimulates the production of ﬁbrous ECM from activated
HSCs/myoﬁbroblasts. The accumulated ECM proteins in turn activate
integrins, then these activated integrins and co-existing growth factors
inhibit theTGF-β1-induced growth-suppressive signals via the formation of
pSmadL, leading to the resistance of hepatocytes to apoptosis, and the
promotion of hepatocarcinogenesis.
matrix become resistant to TGF-β1-induced apoptosis by decreas-
ing caspase activation through FAK-mediated Akt signaling, while
hepatocytes on soft collagen gels are sensitive to apoptosis (Godoy
et al., 2009). Matrix stiffness modulates the growth of Huh7 and
HepG2 HCC cells, as well as cisplatin-induced apoptosis. A stiff
matrix enhances the mitogenic activity through β1-integrin and
FAK,activating the ERK,Akt, and STAT3pathways, andpromoting
the survival of HCC cells after cisplatin treatment. Furthermore,
an increased stiffness promotes the EMT of HCC cells, suggest-
ing the contribution of the mechanical properties of the EMC to
tumor invasion and metastasis (Schrader et al., 2011).
ALTERATIONS OF THE SMAD PHOSPHORYLATION STATUS DURING THE
PROGRESSION OF CHRONIC LIVER DISEASE
When TGF-β1 exerts growth-inhibitory effects on epithelial cells,
the TβRI-mediated phosphorylation of Smad TFs (Smad2/3)
occurs at their C-terminal region (SSXS motif). Recent studies
have shown that the linker region of Smad proteins could be phos-
phorylated by various kinases, including MAP kinases (ERK, p38,
JNK), CDK, and ROCK (Kretzschmar et al., 1999; Matsuura et al.,
2004; Mori et al., 2004; Kamaraju and Roberts, 2005; Wrighton
et al., 2009; Burch et al., 2011) to modulate the transcriptional
activity of the Smad complex, resulting in the escape of cells from
apoptosis and the induction of EMT that contributed to tumor
development and progression.
During the chronic inﬂammation of the liver, altered phospho-
rylation patterns of the Smad2 and Smad3 proteins are observed.
Along with the progression of chronic liver disease, the site of
phosphorylation in the Smad proteins induced by TGF-β1 is
shifted from the C-terminal region (pSmadC) to the linker region
(pSmadL) in activated HSCs and hepatocytes (Yoshida et al., 2005;
Matsuzaki et al., 2007;Murata et al., 2009;Matsuzaki, 2011). Phos-
phorylation of the linker region of Smad2/3 in HCSs is caused by
the activation of JNK through PDGF, leading to the sustained
activation of HSCs, differentiation to myoﬁbroblast-like cells and
continued production of collagen-rich ECM. In hepatocytes in
the earlier stages of chronic liver disease, TGF-β1 induces the C-
terminal phosphorylation of Smad (pSmadC). However, in the
later stage of chronic liver disease when ﬁbrosis in the liver has
advanced, the linker-pSmadL in hepatocytes become prominent,
and TGF-β1-induced growth inhibition is attenuated. The loss of
TGF-β1-induced growth inhibition might be a marker for the pre-
neoplastic changes of hepatocytes, and the dominance of pSmadL
could be a useful indicator of the development of HCC (Matsuzaki
et al., 2007; Murata et al., 2009; Matsuzaki, 2011).
In HCC cells, alterations in the Smad phosphorylation pat-
terns modify the cellular responses to TGF-β1. Blockade of the
C-terminal phosphorylation of Smad2 in HCC cells by transfect-
ing mutant plasmids in which the C-terminal serine residues are
substituted with alanine inhibited TGF-β1-induced pro-apoptotic
Smad-mediated transcriptional activities (Sugano et al., 2003).
Both growth factors and integrins regulate the phosphorylation
pattern of Smads andmodulate the cellular behavior. The presence
of ECM proteins or overexpression of β1-integrin both induced
the phosphorylation of the linker region of Smad2 and Smad3
and blocked the TGF-β1-induced C-terminal phosphorylation
(Hamajima et al., 2009). Accordingly, increased phosphorylation
at the linker region of Smad3 in the hepatocytes adjacent to
the ﬁbrous area in livers infected with chronic hepatitis C has
been observed, thus suggesting a role for the ECM on the linker
phosphorylation of Smad3 (Matsuzaki et al., 2007).
When integrins attenuate the activation of TGF-β1-induced
apoptosis, the expression of PDCD4, a pro-apoptotic molecule
downstream of TGF-β1, is repressed (unpublished data). ERK and
JNK inhibitors, but not a p38 inhibitor, restored the formation of
pSmad2C. All three inhibitors restored pSmad3C formation, and
the transfection of a linker region mutated Smad3, but not Smad2,
restored the TGF-β1-induced transcriptional activity, suggesting
the differential roles of Smad2 and Smad3 (Hamajima et al., 2009;
Matsuzaki, 2011).
FUTURE PERSPECTIVES FOR PREVENTION AND THERAPY
Recent studies have shown that the phosphorylation state of the
Smad TFs plays a pivotal role in converting the tumor suppressor
signal of TGF-β1 to a tumor promoting signal. Thus, the inhibi-
tion of the linker phosphorylation of Smads could be an attractive
approach to inhibit the development and progression of HCC.
Among the kinases that phosphorylate the linker region of Smads
directly or indirectly, JNK has been shown to phosphorylate the
linker regions of both Smad2 and Smad3. Indeed, administration
of a JNK inhibitor to rats successfully inhibited the development
of HCC in a DEN-induced HCC model (Nagata et al., 2009).
Integrins can propagate the multiple signals that promote the sur-
vival and growth of HCC cells by interacting with growth factor
receptors, including the TGF-β receptor. Therefore inhibitors of
integrin activation, which might modulate the phosphorylation
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of Smad indirectly, could represent an alternative approach for the
prevention and/or treatment of HCC and tumor progression. In
fact, antisense-mediated inhibition of integrin αv or integrin β3
suppressed the growth of HCC cells injected subcutaneously in a
mouse model (Li et al., 2007). Various types of integrin inhibitors
are currently being examined in preclinical and clinical studies
(Desgrosellier and Cheresh, 2010; Millard et al., 2011). Further
studies are necessary to clarify the interaction between integrins
and TGF-β1, and will contribute to the development of novel
therapeutics for HCC.
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